Globus Medical (GMED) | Financial Analysis & Statements

Globus Medical Inc. | Mid-cap | Healthcare

58,86 US$

-0,07 %

| Globus Medical Stock Comparison:

Globus Medical vs Abbott Laboratories Globus Medical vs Boston Scientific Globus Medical vs Masimo Globus Medical vs Bio-Rad Globus Medical vs Bio-Rad Laboratories Globus Medical vs S&P 500 | Market

Overview Income Statement Balance Sheet Cash Flow Key Ratios Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 2,5B

Gross Profit 1,5B 58,90 %

Operating Income 219,7M 8,72 %

Net Income 103,0M 4,09 %

EPS (Diluted) 0,75 US$

Balance Sheet Metrics

Total Assets 5,3B

Total Liabilities 1,1B

Shareholders Equity 4,2B

Debt to Equity 0,26

Cash Flow Metrics

Operating Cash Flow 444,1M

Free Cash Flow 405,2M

Revenue & Profitability Trend

Income Statement

Metric	2024	2023	2022	2021	2020
Revenue	2,5B	1,6B	1,0B	958,1M	789,0M
Cost of Goods Sold	1,0B	548,2M	263,7M	239,2M	217,5M
Gross Profit	1,5B	1,0B	759,1M	718,9M	571,6M
Operating Expenses	1,1B	767,4M	505,1M	505,5M	439,3M
Operating Income	219,7M	201,8M	236,3M	194,9M	115,5M
Pre-tax Income	120,7M	165,4M	243,0M	180,4M	125,9M
Income Tax	17,7M	42,5M	52,8M	31,2M	23,6M
Net Income	103,0M	122,9M	190,2M	149,2M	102,3M
EPS (Diluted)	0,75 US$	1,07 US$	1,85 US$	1,44 US$	1,01 US$

Income Statement Trend

Balance Sheet

Metric	2024	2023	2022	2021	2020
Assets
Current Assets	2,2B	1,9B	983,3M	864,5M	821,8M
Non-Current Assets	3,1B	3,2B	1,1B	1,1B	857,7M
Total Assets	5,3B	5,1B	2,1B	2,0B	1,7B
Liabilities
Current Liabilities	855,9M	392,3M	159,2M	140,2M	120,8M
Non-Current Liabilities	218,5M	695,8M	70,5M	75,7M	52,4M
Total Liabilities	1,1B	1,1B	229,8M	215,9M	173,2M
Equity
Total Shareholders Equity	4,2B	4,0B	1,8B	1,7B	1,5B

Balance Sheet Composition

Cash Flow Statement

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income	103,0M	122,9M	190,2M	149,2M	102,3M
Operating Cash Flow	444,1M	221,9M	170,6M	254,0M	170,2M
Investing Activities
Capital Expenditures	-115,4M	-78,3M	-74,0M	-56,9M	-63,7M
Investing Cash Flow	-176,1M	303,0M	-110,4M	-375,9M	-117,3M
Financing Activities
Dividends Paid	-	-	-	-	-
Financing Cash Flow	-138,1M	-244,2M	-151,7M	54,1M	-38,7M
Free Cash Flow	405,2M	165,2M	104,4M	219,4M	135,1M

Cash Flow Trend

Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 43,96

Forward P/E 17,22

Price to Book 1,95

Price to Sales 3,18

PEG Ratio 17,22

Profitability Ratios

Profit Margin 7,39 %

Operating Margin 16,40 %

Return on Equity 4,63 %

Return on Assets 5,90 %

Financial Health

Current Ratio 4,44

Debt to Equity 2,27

Beta 1,21

Per Share Data

EPS (TTM) 1,34 US$

Book Value per Share 30,20 US$

Revenue per Share 18,45 US$

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
gmed	8,0B	43,96	1,95	4,63 %	7,39 %	2,27
Abbott Laboratories	232,9B	17,38	4,77	30,65 %	31,89 %	27,09
Boston Scientific	147,6B	72,80	6,64	9,50 %	11,58 %	52,16
Masimo	8,7B	129,16	9,24	-25,07 %	-23,25 %	72,01
Bio-Rad	6,8B	-3,83	1,03	-27,52 %	-85,16 %	20,50
Bio-Rad Laboratories	6,2B	-3,47	0,94	-27,52 %	-85,16 %	20,50

Financial data is updated regularly. All figures are in the company's reporting currency.